Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171772 | 0.82 | LMNA (0.39) | LMNACYP2C9 | |
| SCHEMBL23862172 | 0.78 | LMNA (0.33) | LMNACYP2C9 | |
| SCHEMBL16134346 | 0.72 | LMNA (0.36) | LMNACYP2C9 | |
| SCHEMBL13708301 | 0.72 | LMNA (0.36) | LMNACYP2C9 | |
| SCHEMBL16134342 | 0.72 | LMNA (0.36) | LMNACYP2C9 | |
| SCHEMBL149596 | 0.71 | — | — | |
| SCHEMBL18725576 | 0.70 | LMNA (0.31) | LMNACYP2C9 | |
| SCHEMBL16867072 | 0.70 | LMNA (0.34) | LMNACYP2C9 | |
| SCHEMBL21677289 | 0.69 | LMNA (0.33) | LMNACYP2C9 | |
| SCHEMBL10788080 | 0.67 | CYP2C9 (0.40) | LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581035-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024049931-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | TOP1, TOP2A, TOP2B | LMNA 143/4885CYP2C9 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.